66 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
paid us an initial upfront payment of $20 million in exchange for exclusive licenses to two of our targets, MAGE-A4 and an undisclosed target … of KIMMTRAK to patients in France is also required in the assessment of rebates payable. We apply judgement to assess internal targets, pricing information
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development
Be the Best … on performance against strategic, corporate targets and the overall performance of the business over the year, 110% of the target bonus was awarded, which
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development
Be the Best … on performance against strategic, corporate targets and the overall performance of the business over the year, 110% of the target bonus was awarded, which
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen
10-K
8v9msw2samw
28 Feb 24
Annual report
7:33am
8-K
EX-99.2
2zvy hu0gcxv56wz5k
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.1
e7igk81u7 kf798
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.3
6lx14qrgiiexubt3u
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
saba ulq1u
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
q4b4ip fm
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
ke9k8h59v yttba
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
49c5 ek2wb40spk7o
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.3
h4ueo8nv
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
m68gqx5n
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
svz19ehhlk7l0u
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
e45dluvl dy5pyx
18 Apr 23
Current report (foreign)
4:13pm
6-K
EX-99.1
jqdn5khv5tcww t7czz
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K/A
EX-99.1
ui3y69hxdqisi
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.1
cu3n2cm2
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am